https://orcid.org/0000-0003-0064-8707
Figures & data
Table 1. Baseline characteristics.
Figure 1. Switch rates over 24 months among biologics for patients with psoriasis [A] by biologic class, and [B] by individual biologic. Censoring is defined as the 24-month follow-up, first switch to apremilast/another biologic or end of continuous enrollment, whichever occurs first. CI: confidence interval; IL: interleukin; TNF: tumor necrosis factor.
![Figure 1. Switch rates over 24 months among biologics for patients with psoriasis [A] by biologic class, and [B] by individual biologic. Censoring is defined as the 24-month follow-up, first switch to apremilast/another biologic or end of continuous enrollment, whichever occurs first. CI: confidence interval; IL: interleukin; TNF: tumor necrosis factor.](/cms/asset/350d4def-da3c-4b5d-81db-b6038d2617ea/ijdt_a_2200870_f0001b_c.jpg)
Figure 1a. Continued.
Figure 2. Adjusted risk of switching therapy by class of biologic. IL-23 inhibitor is the reference group. P value based on multivariable Cox regression models adjusting for baseline demographics (geographic region, gender, age), baseline provider type (dermatologist, rheumatologist, both, none), clinical comorbidities (anxiety/depression, major adverse cardiovascular event, hypertension, obesity, diabetes), and treatment characteristics (previous TIM use and index biologic class). CI: confidence interval; HR: hazard ratio; IL: interleukin; TIM: new targeted immune modulator; TNF: tumor necrosis factor.
Table 2. Predictors of switching biologic therapy: adjusted results from multivariable Cox regression analysis.
Supplemental Material
Download PDF (335.5 KB)Data availability statement
The data that support the findings of this study are available from Merative® MarketScan® Research. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the corresponding author upon request with permission from Merative® MarketScan® Research.